Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Caribou Biosciences, Inc. Market Cap
Based on ratings from 9 stock analysts, the Caribou Biosciences, Inc. stock price is expected to increase by 486.85% in 12 months. This is calculated by using the average 12-month stock price forecast for Caribou Biosciences, Inc.. The lowest target is $3 and the highest is $26. Please note analyst price targets are not guaranteed and could be missed completely.
Caribou Biosciences, Inc. has a total of 9 Wall St Analyst ratings. There are 7 buy ratings, 2 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Caribou Biosciences, Inc. will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of CRBU.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Yigal Nochomovitz Citigroup | Buy | $6 | Maintains | Nov 26, 2024 |
| Robert Burns HC Wainwright & Co. | Buy | $9 | Reiterates | Nov 15, 2024 |
| Robert Burns HC Wainwright & Co. | Buy | $9 | Reiterates | Sep 3, 2024 |
| Robert Burns HC Wainwright & Co. | Buy | $9 | Reiterates | Aug 14, 2024 |
| Luca Issi RBC Capital | Outperform | $14 | Reiterates | Aug 7, 2024 |
| Robert Burns HC Wainwright & Co. | Buy | $9 | Reiterates | Jul 17, 2024 |
| Robert Burns HC Wainwright & Co. | Buy | $9 | Maintains | Jun 4, 2024 |
| Asthika Goonewardene Truist Securities | Buy | $19 | Maintains | May 16, 2024 |
| Robert Burns HC Wainwright & Co. | Buy | $24 | Reiterates | May 13, 2024 |
| Robert Burns HC Wainwright & Co. | Buy | $24 | Maintains | Mar 19, 2024 |
| Luca Issi RBC Capital | Outperform | $19 | Reiterates | Mar 12, 2024 |
| Rick Bienkowski Cantor Fitzgerald | Neutral | Initiates | Nov 8, 2023 | |
| Robert Burns HC Wainwright & Co. | Buy | $23 | Maintains | Jul 26, 2023 |
Truist Securities | Buy | Reiterates | Jul 14, 2023 | |
| Asthika Goonewardene Truist Securities | Buy | $23 | Initiates | Jul 11, 2023 |
| Robert Burns HC Wainwright & Co. | Buy | $25 | Maintains | May 10, 2023 |
| Robert Burns HC Wainwright & Co. | Buy | $26 | Maintains | Mar 14, 2023 |
| Mark Breidenbach Oppenheimer | Outperform | $32 | Maintains | Mar 10, 2023 |
| Luca Issi RBC Capital | Outperform | $19 | Reiterates | Mar 10, 2023 |
| Yigal Nochomovitz Citigroup | Buy | $38 | Maintains | Aug 29, 2022 |
When did it IPO
N/A
Staff Count
158
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Rachel E. Haurwitz Ph.D.
Market Cap
$196.5M
In 2023, CRBU generated $34.5M in revenue, which was a increase of 148.91% from the previous year. This can be seen as a signal that CRBU's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Wed, 20 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Caribou Biosciences' CEO, Rachel Haurwitz, will participate in upcoming investor conferences, highlighting the company's ongoing engagement with the investment community.
Why It Matters - Rachel Haurwitz's participation in investor conferences can enhance Caribou Biosciences' visibility, potentially attracting new investment and influencing stock performance.
Mon, 18 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - A proposed class action settlement has been approved by the U.S. District Court for Northern California for purchasers of Caribou Biosciences, Inc. (NASDAQ: CRBU) common stock.
Why It Matters - The approved class action settlement for Caribou Biosciences may impact stock value and investor sentiment, signaling potential legal risks and financial implications for the company.
Wed, 06 Nov 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - Caribou Biosciences, Inc. (CRBU) reported a quarterly loss of $0.38 per share, better than the expected loss of $0.44, but worse than a $0.12 loss per share a year earlier.
Why It Matters - Caribou Biosciences' smaller-than-expected loss indicates improving performance, which may enhance investor confidence and sentiment towards the stock.
Mon, 30 Sep 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - Caribou Biosciences (CRBU) is developing allogeneic CAR-T therapies using its chRDNA technology. Its candidate CB-010 is in Phase 1 trials for large B cell lymphoma, showing promising results.
Why It Matters - Caribou Biosciences' advanced chRDNA technology and promising Phase 1 trial results for CB-010 may enhance its competitive edge, impacting stock performance and investment potential in biotech.
Mon, 19 Aug 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - Pomerantz LLP is investigating claims for Caribou Biosciences, Inc. (NASDAQ: CRBU) investors. Interested parties can contact Danielle Peyton for details.
Why It Matters - Investors in Caribou Biosciences may face potential legal issues, which could impact stock performance and investor sentiment, highlighting risks associated with the company.
Mon, 12 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Caribou Biosciences appointed Dr. Tina Albertson as chief medical officer, bringing 15 years of experience in CAR-T therapies, to lead clinical and regulatory efforts for its programs.
Why It Matters - The appointment of Dr. Albertson strengthens Caribou Biosciences' leadership in CAR-T therapies, potentially enhancing clinical development success and investor confidence in upcoming trials.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
